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Crossing barriers in transplantation
In 1978, Jonathan Sprent and Robert Korngold proved that graft-versus-
host disease (GVHD) is caused by donor T cells that attack the host’s 
non-MHC antigens. T cell depletion of donor grafts has since become 
a staple of transplantation strategies to combat leukemia and other 
inherited blood disorders.
GVHD occurs in about half the patients 
who receive bone marrow transplants 
(BMT) from HLA-matched donors and 
results in multiple organ failure and 
death (1). Early anti-GVHD strategies 
using immunosuppressive drugs were 
unsuccessful and they inhibited immune 
cells from both graft and host. A graft-
specific strategy was hard to develop as 
the cellular events that led to GVHD 
were still unclear.
Minor antigens, major disease
In mid-1970, Sprent, then a postdoctoral 
fellow at the Basel Institute of Immunol-
ogy, was studying tolerance to histo-
compatibility antigens in bone marrow 
chimeras. He, along with Harald von 
Boehmer, found that preventing GVHD 
in mice was relatively easy. Bone mar-
row harvested from MHC-incompatible 
parents and depleted of T cells did not 
cause GVHD when transferred into irra-
diated mice (2). They attributed this 
finding to the absence of mature donor 
T cells and the induction of tolerance 
when the donor stem cells matured into 
new T cells in the host thymus.
The clinicians who were struggling to 
contain GVHD in human patients were, 
however, unimpressed. At a transplanta-
tion conference in 1976, the skeptics ve-
hemently pointed out that GVHD in fact 
occurred between HLA-matched donors 
who only differed in their expression of 
non-HLA antigens—called “minor histo-
compatibility antigens” (mHA). “They 
dismissed our mouse model as being ir-
relevant,” recalls Sprent. He was challen-
ged to produce a transplant model where 
GVHD occurred in MHC-matched mice 
across a mHA barrier and then find a 
way of overcoming the disease.
A new model
Sprent, who was by now a faculty mem-
ber at the University of Penn  sylvania 
(Philadelphia), and Robert Korngold, a 
newly arrived Ph.D. student, began 
transplanting bone marrow cells be-
tween various pairs of mice matched 
for MHC but not for mHA. Perhaps 
due to the extremely low numbers of 
mature T cells in mouse (but not hu-
man) bone marrow, only 2 of the 11 
strain combinations studied got lethal 
GVHD. Nevertheless, disease devel-
oped in the other pairs when spleen 
and lymph node cells were mixed in 
with the bone marrow cells, suggesting 
a role for mature T cells in GVHD. 
This theory was confirmed when T 
cell–depleted bone marrow failed to 
induce GVHD in the lethal combina-
tions. The team also showed that it 
only took 3 × 104 T cells in the graft 
to mount a lethal response against the 
host. They published these results in 
1978 in a landmark paper in the Journal 
of Experimental Medicine (3).
In the next few years, Korngold and 
Sprent used this model to define other 
features of T cell–mediated GVHD. 
They found that the mHA were being 
presented to donor T cells by the class I 
MHC of the recipient (4), and that 
both CD4 and CD8 T cells caused 
lethal disease but their relative contri-
butions were strain dependent (5). In 
the meantime, T cell depletion of donor 
grafts was being tried out in cancer 
clinics around the world.
Improving treatment
These human studies confirmed that 
T cell depletion lowered the risk of 
GVHD, but other problems were crop-
ping up. Graft rejection went from 
being a rare to a common problem. 
“We were finding out that the no-free-
lunch theory was true in medicine as 
well,” says Robertson Parkman, who 
directs transplantation research at the 
Children’s Hospital of Los Angeles.
Depleted grafts also had no mature 
T cells to attack the host’s leukemic cell 
population. For reasons that are not yet 
clear, this graft versus leukemia activity 
was not fully effective even once the 
grafted cells had fully differentiated. 
Graft recipients were further compro-
mised by pretransplant irradiation and 
posttransplant immunosuppressive drugs 
that allowed latent viral infections to 
become reactivated.
Parkman and others now allow 
time for the depleted graft to establish 
itself before adding back donor T cell 
populations that have been filtered for 
GVHD-causing T cells and enhanced 
for antileukemic activity. These meth-
ods have not yet produced a foolproof 
cure, but better transplantation combined 
with new drugs have increased the 
five-year survival rate to 80% in pa-
tients with chronic leukemia (6), a great 
improvement over the 35% that was 
common before the experiments of 
Korngold and Sprent.
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